References
You can view the abstracts for the references listed below via the National Library of Medicine’s PubMed service. Just click the PubMed links. Click here to view the PubMed disclaimer and copyright notice.
- 1.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799.
Link to abstract on PubMed - 2.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
Link to abstract on PubMed - 3.
Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119-128.
Link to abstract on PubMed - 4.
Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis. Oncogene. 1991;6:1915-1922.
Link to abstract on PubMed - 5.
Klefstrom J, Västrik I, Saksela E, Valle J, Eilers M, Alitalo K. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 1994;13:5442-5450.
Link to abstract on PubMed - 6.
Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene. 1998;17:339-346.
Link to abstract on PubMed - 7.
Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517.
Link to abstract on PubMed - 8.
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307-315.
Link to abstract on PubMed - 9.
Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003;22:7414-7430.
Link to abstract on PubMed - 10.
Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-885.
Link to abstract on PubMed - 11.
Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev. 2005;57:187-215.
Link to abstract on PubMed - 12.
Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol. 2006;3:388-398.
Link to abstract on PubMed - 13.
Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-418.
Link to abstract on PubMed - 14.
Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (Review). Int J Oncol. 1998;12:141-152.
Link to abstract on PubMed - 15.
Filomenko R, Prévotat L, Rébé C, et al. Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene. 2006;25:7635-7645.
Link to abstract on PubMed - 16.
Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20:1063-1075.
Link to abstract on PubMed - 17.
Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61:1645-1651.
Link to abstract on PubMed - 18.
Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;19;274:7987-7992.
Link to abstract on PubMed - 19.
Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003;8:413-450.
Link to abstract on PubMed - 20.
Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem. 2004;279:51057-51067.
Link to abstract on PubMed - 21.
Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998;58:4561-4566.
Link to abstract on PubMed - 22.
Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22:9030-9040.
Link to abstract on PubMed - 23.
Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005;331:851-858.
Link to abstract on PubMed - 24.
Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
Link to abstract on PubMed - 25.
Lee JM, Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A. 1993;90:5742-5746.
Link to abstract on PubMed - 26.
Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the response to therapeutic agents. J Clin Invest. 1999;104:263-269.
Link to abstract on PubMed - 27.
Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor—related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630.
Link to abstract on PubMed - 28.
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
Link to abstract on PubMed - 29.
Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;97:458-465.
Link to abstract on PubMed - 30.
Mühlethaler-Mottet A, Bourloud KB, Auderset K, Joseph JM, Gross N. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene. 2004;23:5415-5425.
Link to abstract on PubMed - 31.
Ravi R, Jain AJ, Schulick RD, et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 2004;64:9105-9114.
Link to abstract on PubMed - 32.
Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998;4:232-234.
Link to abstract on PubMed - 33.
Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002;12:193-213.
Link to abstract on PubMed - 34.
Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 2005;115:2648-2655.
Link to abstract on PubMed - 35.
Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001-1012.
Link to abstract on PubMed